Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens

Biomedicine and Pharmacotherapy

Volumn 64, Issue 4, 2010, Pages 275-281

  Martín Castillo, Antonia ^a   Castells, Maria Teresa ^b   Adánez, Gracia ^c   Polo, Maria Teresa Sánchez ^c   Pérez, Bartolomé García ^c   Ayala, Ignacio ^b  

^a Digestive Service   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Atorvastatin; Chicken; Hyperlipidemic diet; Non alcoholic fatty liver disease activity score (NAS); Steatohepatitis

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHICKEN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIET; DISEASE ACTIVITY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HYPERLIPIDEMIA; INFLAMMATORY INFILTRATE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID DIET; LIPID LIVER LEVEL; MALE; MORNING DOSAGE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CHICKENS; CHOLESTEROL; DISEASE MODELS, ANIMAL; FATTY LIVER; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INFLAMMATION; MALE; PYRROLES; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 77952323601     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.06.003     Document Type: Article

References (27)

1. Rector R.S., Thyfault J.P., Wei Y., Ibdah J.A. Non-alcoholic fatty liver disease and the metabolic syndrome: An update. World J Gastroenterol 2008, 14:185-192.
2. George J., Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol Pharmacol 2008, 5:49-59.
3. Schreuder T.C.M.A., Verwer B.J., van Nieukerk C.M.J., Mulder C.J.J. Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008, 14:2474-2486.
4. London R.M., George J. Pathogenesis of NASH: animal models. Clin Liver Dis 2007, 11:55-74.
5. Cherian G., Holsonbake T., Goeger M., Bildfell R., Dietary CLA alters yolk and tissue FA composition and hepatic histopathology of laying hens. Lipids 2002, 37:751-757.
6. García-Fuentes E., Gil-Villarino A., Zafra M.F., García-Peregrín E. Differential changes in the fatty acid composition of the main lipid classes of chick plasma induced by dietary coconut oil. Comp Biochem Physiol B 2002, 133:269-275.
7. García Pérez B., Ayala I., Castells M.T., Sánchez Polo M.T., García Partida P., Valdés M. Effects of nifedipine, verapamil and diltiazem on serum biochemical parameters and aortic composition of atherosclerotic chickens. Biomed Pharmacother 2005, 59:1-7.
8. Anfossi G., Massucco P., Bonomo K., Trovati M. Prescription of statins to dyslipidemic patients affected by liver disease: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis 2004, 14:215-224.
9. Chitturi S., George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsivants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002, 22:169-183.
10. Kostner G.M., Molinari E., Pichler P. Evaluation of a new HDL2/HDL3 quantitation method based on precipitation with polyethylene glycol. Clin Chem Acta 1985, 148:139-147.
11. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
12. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
13. Kleiner D.E., Brunt E.M., Van Natta M., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histologic scoring system for non-alcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
14. Ayala I., Martín Castillo A., Adánez G., Fernández-Rufete A., García Pérez B., Castells M.T. Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis. Exp Biol Med 2009, 234:10-16.
15. Cortez-Pinto H., Camilo M.E., Baptista A., De Oliveira A.G., De Moura M.C. Non-alcoholic fatty liver: another feature of the metabolic syndrome?. Clin Nutr 1999, 18:353-358.
16. Amagasa H., Okazaki M., Iwai S., Kumai T., Kobayashi S., Oguchi K. Enhancement of the coagulation system in spontaneously hypertensive and hyperlipidemic rats. J Atheroscler Thromb 2005, 12:191-197.
17. Okazaki M., Morio Y., Iwai S., Miyamoto K., Sakamoto H., Imai K., et al. Age-related changes in blood coagulation and fibrinolysis in mice fed on a high-cholesterol diet. Exp Anim 1998, 47:237-246.
18. Ichino K., Okazaki M., Usami S., Oguchi K. Involvement of enhanced coagulation and fibrinolysis system in induction of atherosclerosis in hyperlipidemic rabbits fed on a high cholesterol diet. In Vivo 1997, 11:115-123.
19. Elkin R.G., Wood K.V., Hagey L.R. Biliary bile acid profiles of domestic fowl as determined by high performance liquid chromatography and fast atom bombardment mass spectrometry. Comp Biochem Physiol B Biochem Mol Biol 1990, 96:157-161.
20. Egawa T., Toda K., Nemoto Y., et al. Pitavastain ameliorates severe hepatic steatosis in aromatasedeficient (Ar-/-) mice. Lipids 2003, 38:519-523.
21. Elkin R.G., Zhong Y., Donkin S.S., Hengstschläger-Ottnad E., Schneider W.J. Effects of atorvastatin on lipid metabolism in normolipidemic and hereditary hyperlipidemic, non-laying hens. Comp Biochem Physiol B Biochem Mol Biol 2006, 143:319-329.
22. Sanguino E., Roglans N., Alegret M., Sánchez R.M., Vazquez-Carrera M., Laguna J.C. Atorvastatin reverses age-related reduction in rat hepatic PPARα and HNF-4. Br J Pharmacol 2005, 145:853-861.
23. Ekstedt M., Franzén L.E., Mathiesen U.L., Holmqvist M., bodemar G., Kechaqias s. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study. J Hepatol 2007, 47:135-141.
24. Georgescu E., Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007, 16:39-46.
25. Dunzendorfer S., Rothbucher D., Schratzberger P., Reinisch N., Kahler C.M., Wiedermann C.J. Mevelonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 1997, 81:963-969.
26. Lee R.G. Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. Hepatology 1995, 21:1742-1743.
27. Hübscher S.G. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006, 49:450-465.